Phase 2 Study of Perioperative Pembrolizumab and Sacituzumab Govitecan in Muscle-Invasive Bladder Cancer Unfit for Cisplatin Therapy
- Trial ID
- 2024-514569-20-00
- Protocol
- SURE-02
- Sponsor
- Ospedale San Raffaele S.r.l.
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to assess whether the combination of **sacituzumab govitecan** and **pembrolizumab** serves as an effective perioperative strategy for patients with clinical T2-3bN0M0 muscle-invasive bladder cancer (MIBC) who are unable or unwilling to receive cisplatin-based chemotherapy. This is clinically relevant as it explores alternative treatment options for a subset of MIBC patients who have limited therapeutic choices due to contraindications or refusal of standard chemotherapy.
Secondary objectives include:
- Evaluating the proportion of patients who achieve a pathological response.
- Assessing the surgical and medical safety of the neoadjuvant combination therapy and the adjuvant pembrolizumab therapy.
- Determining survival outcomes, specifically event-free survival and overall survival, in the total population and subgroups based on pathological response.
Participants
The clinical trial involves participants diagnosed with **muscle-invasive bladder cancer** (MIBC), specifically those with clinical stage T2-3bN0M0 who are ineligible or refuse cisplatin-based chemotherapy. The study population includes both male and female subjects over the age of 18, with no upper age limit specified. Participants are required to have adequate hepatic and renal function, as well as an ECOG performance status score of 0 or 1, indicating they are fully active or restricted in physically strenuous activity but ambulatory. The trial does not specify the total number of participants, as this information was not provided by the sponsor. Both genders are included, and the trial population is selected based on their ability to understand and provide informed consent, as well as their medical suitability for the study's interventions. Lifestyle considerations such as diet and physical activity are not detailed, but participants must meet specific health criteria, including adequate hematologic counts and a histopathologically confirmed diagnosis of urothelial carcinoma with a dominant transitional cell pattern. The trial also includes a vulnerable population, although specific details about this group are not provided.
Plans and Procedures
The clinical trial is designed as an open-label, single-arm, phase 2 study to evaluate the efficacy of a **perioperative** strategy involving **pembrolizumab** and **sacituzumab govitecan** in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse cisplatin-based chemotherapy. The trial aims to assess the clinical complete response rate as the primary endpoint, with secondary endpoints including bladder-intact event-free survival, pathological response rate, safety according to CTCAE v-5.0, and overall survival. The study is expected to run from June 2021 to December 2026, with a maximum treatment period of 51 weeks for pembrolizumab and 12 weeks for sacituzumab govitecan.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, hepatic function, creatinine clearance, and ECOG performance status. The screening will also ensure that female participants of childbearing potential have a negative pregnancy test and agree to use effective contraception. Following the screening, participants will receive the investigational drugs via **intravenous infusion**. Regular follow-up visits will monitor the participants' response to treatment and any adverse effects. The end-of-study visit will evaluate the overall outcomes and gather final data on the endpoints.
Participant involvement is expected to last for the duration of the treatment period, with additional time for follow-up assessments. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any medical condition that contraindicates continued participation. The trial is conducted under strict adherence to ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.
Treatment
The clinical trial involves the administration of **pembrolizumab**, marketed under the name Keytruda, which is provided as a 25 mg/mL concentrate for solution for infusion. This pharmaceutical form is intended for **intravenous infusion**. The maximum daily dose of pembrolizumab is 200 mg, with a total maximum dose of 200 mg per treatment cycle. The treatment period extends up to 51 weeks. Pembrolizumab is a protein-based therapeutic agent, specifically classified as a monoclonal antibody, and is produced by Merck Sharp & Dohme B.V. The administration schedule and participant compliance are monitored to ensure adherence to the dosing regimen.
Additionally, the trial includes the use of **sacituzumab govitecan**, marketed as Trodelvy, which is supplied as a 200 mg powder for concentrate for solution for infusion. This medication is also administered via **intravenous use**. The dosing regimen for sacituzumab govitecan is based on body weight, with a maximum daily dose of 7.5 mg/kg and a total maximum dose of 15 mg/kg per treatment cycle. The treatment duration for sacituzumab govitecan is up to 12 weeks. Sacituzumab govitecan is an antibody-drug conjugate, produced by Gilead Sciences Ireland Unlimited Company. The trial protocol includes measures to monitor dosing schedules and ensure participant compliance with the treatment regimen.
Efficacy
Efficacy in this clinical trial will be assessed using both primary and secondary endpoints. The primary endpoint is the clinical complete response (CR) rate, which will evaluate the effectiveness of the treatment regimen in achieving a complete response in patients with muscle-invasive bladder cancer (MIBC). Secondary endpoints include bladder-intact event-free survival (BI-EFS), pathological response rate, safety as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and overall survival (OS). These endpoints will provide a comprehensive assessment of the treatment's impact on disease progression, patient safety, and survival outcomes.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Female or male subjects, >18 years of age, able to understand and give written informed consent
- Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 3 months after the last dose of study therapy.
- Clinical stage T2-T3bN0M0 MIBC, assessed by CT + PET/CT + pelvic MRI.
- The patient accepts to undergo RC.
- Ineligibility to receive cisplatin-based neoadjuvant chemotherapy based on Galsky’s criteria OR refusal to receive neoadjuvant cisplatin-based chemotherapy.
- Histopathologically confirmed urothelial carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern.
- Fit and planned for RC (according to local guidelines).
- ECOG performance status score of 0 or 1
- Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (Hemoglobin ≥ 9 g/dL, ANC ≥ 1,500/ mm3, and Platelets ≥ 100,000/ μL)
- Adequate hepatic function (Bilirubin ≤ 1.5 IULN, AST and ALT ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin >3 g/dl)
- Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation
- Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication, and must not be lactating. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- Female subjects of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >2 years
- Refusal of unsuitability for standard chemoradiotherapy protocols.
Exclusion Criteria
- Have received prior systemic anti-cancer therapy including investigational agents and immunotherapy.
- Have received prior radiotherapy on the bladder tumor.
- Have received a partial cystectomy.
- Refusal to undergo RC.
- Have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
- Have received any antibiotics within 30 days prior to the first dose of study drug.
- Are currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
- Have a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Participants with low-risk early stage prostate cancer defined as follows are not excluded; Stage T1c or T2a with a Gleason score ≤ 6 and prostatic-specific antigen (PSA) < 10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation.
- Have severe hypersensitivity (≥Grade 3) to pembrolizumab or sacituzumab govitecan and/or any of its excipients.
- Have active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Have a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- Have nephrostomy, central venous catheters, any other types of catheters that could make the patient at higher risk of developing severe infectious complications during treatment with sacituzumab govitecan.
- Have >/= 3 risk factors for the development of febrile neutropenia according to the ASCO guidelines (Smith et al, J Clin Oncol. 2015;33:3199-3212). These risk factors are the following: Age >65 years, advanced disease, Previous chemotherapy or radiation therapy, Preexisting neutropenia or bone marrow involvement with tumor, infection, Open wounds or recent surgery, Poor performance status or poor nutritional status, Poor renal function, Liver dysfunction, most notably elevated bilirubin, Cardiovascular disease, Multiple comorbid conditions, HIV infection.
- Have a history of inflammatory bowel disease, ulcerative colitis, or any other pre-existing inflammatory or autoimmune disease that could make the patient at higher risk of developing severe diarrhea or related complications.
- Have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Have active cardiac disease, defined as: - Myocardial infarction or unstable angina pectoris within 6 months of C1D1; - History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation; - NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of < 40%
- Have known history of HIV-1/2 infection.
- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
- Have other concurrent medical or psychiatric conditions that, in the Investigator’s opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
- High dose systemic corticosteroids (≥20 mg of prednisolone or its equivalent) are not allowed within 2 weeks of C1D1.
- Have received or are currently receiving (within the previous 2 weeks) antibiotics.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Italy | Not Recruiting | 01 Jun 2021 | 48 |
Sites & Investigators
Research sites
Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Trodelvy 200 mg powder for concentrate for solution for infusion | Test | POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS USE | 7.5 | 12 | PRD9351384 |
KEYTRUDA 25 mg/mL concentrate for solution for infusion | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS INFUSION | 200 | 51 | PRD4323105 |

